BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492-4499. [PMID: 20697072 DOI: 10.1200/jco.2010.29.3241] [Cited by in Crossref: 144] [Cited by in F6Publishing: 157] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Fay CJ, Awh KC, Leboeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1071171] [Reference Citation Analysis]
2 Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98:193-209. [PMID: 36226409 DOI: 10.1002/ajh.26760] [Reference Citation Analysis]
3 Hughes MS, Sterling CH, Varadhan R, Ambinder RF, Jones RJ, Sweren RJ, Rozati S, Bolaños-Meade J, Luznik L, Imus PH, Ali SA, Borrello IM, Huff CA, Jain T, Ambinder A, DeZern AE, Gocke CB, Gladstone DE, Swinnen LJ, Wagner-Johnston ND, Fuchs EJ. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma 2022;63:2987-91. [PMID: 35915978 DOI: 10.1080/10428194.2022.2105330] [Reference Citation Analysis]
4 To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. Front Immunol 2022;13:968395. [DOI: 10.3389/fimmu.2022.968395] [Reference Citation Analysis]
5 Angelov D, Dillon J, Mellerick L, Pender E, Bacon L, Lee G, Higgins L, McCarty H, Gillham C, Quinn J, O'Gorman S, Leonard N, McMenamin M, Vandenberghe E. Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease. Bone Marrow Transplant 2022. [PMID: 35596064 DOI: 10.1038/s41409-022-01713-7] [Reference Citation Analysis]
6 Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022. [PMID: 35589997 DOI: 10.1038/s41409-022-01691-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
7 Scarisbrick JJ. The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas. Presse Med 2022;:104123. [PMID: 35490911 DOI: 10.1016/j.lpm.2022.104123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yonekura K. Current treatment strategies and emerging therapies for cutaneous lymphoma. J Dermatol 2021. [PMID: 34958516 DOI: 10.1111/1346-8138.16289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Franke G, Dumann K, Jentzsch M, Monecke A, Doehring C, Nehring-vucinic C, Schwind S, Niederwieser D, Platzbecker U, Ziemer M, Vucinic V. Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome. Front Oncol 2021;11:749691. [DOI: 10.3389/fonc.2021.749691] [Reference Citation Analysis]
10 Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, Nikolaou V, Pappa V, Papadavid E, Tsirigotis P. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. Clin Hematol Int 2021;3:72-6. [PMID: 34595469 DOI: 10.2991/chi.k.210529.001] [Reference Citation Analysis]
11 Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:1313-28. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
12 Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, Hoppe RT, Kim YH. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv 2020;4:4474-82. [PMID: 32941647 DOI: 10.1182/bloodadvances.2020001627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
13 de Masson A, Peffault de Latour R, Ram-wolff C, Bagot M. Traitement des lymphomes T cutanés par allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:187-192. [DOI: 10.1016/j.fander.2020.07.004] [Reference Citation Analysis]
14 Scheu A, Schnabl SM, Steiner DP, Fend F, Berneburg M, Yazdi AS. Stellenwert diagnostischer Verfahren und Risiko von Zweittumoren bei primär kutanen Lymphomen. J Dtsch Dermatol Ges 2021;19:373-82. [PMID: 33709586 DOI: 10.1111/ddg.14400_g] [Reference Citation Analysis]
15 Prince HM, Abeyakoon C. Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sézary syndrome: never-late, never-never? Bone Marrow Transplant 2021;56:1232-4. [PMID: 33526916 DOI: 10.1038/s41409-020-01150-4] [Reference Citation Analysis]
16 Mascolo M, Travaglino A, Varricchio S, Russo D, Sabattini E, Agostinelli C, Bertuzzi C, Baldo A, Pileri A, Picardi M, Pane F, Staibano S. Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Arch 2021;478:961-8. [PMID: 33098490 DOI: 10.1007/s00428-020-02952-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bolcato V, Barruscotti S, DE Silvestri A, Tomasini CF, Brazzelli V. Sézary Syndrome: a clinico-pathological study of 9 cases. Ital J Dermatol Venerol 2021;156:73-83. [PMID: 33084262 DOI: 10.23736/S2784-8671.19.06403-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Brouwer IJ, Out-Luiting JJ, Vermeer MH, Tensen CP. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. Biochem Biophys Rep 2020;24:100832. [PMID: 33102814 DOI: 10.1016/j.bbrep.2020.100832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Stranzenbach R. How do we treat cutaneous T-cell lymphoma? Ital J Dermatol Venerol 2021;156:534-44. [PMID: 32938164 DOI: 10.23736/S2784-8671.20.06606-7] [Reference Citation Analysis]
21 Kanda-Kato M, Yoshioka S, Ishikawa T. Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome. Case Rep Oncol 2020;13:1053-8. [PMID: 33082748 DOI: 10.1159/000509347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
23 Dimitriou F, Schanz U, Nair G, Kimeswenger S, Brüggen MC, Hoetzenecker W, French LE, Dummer R, Cozzio A, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. Front Med (Lausanne) 2020;7:290. [PMID: 32714935 DOI: 10.3389/fmed.2020.00290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2020;7:CD008946. [PMID: 32632956 DOI: 10.1002/14651858.CD008946.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
25 Ramnaraign BH, Dang NH. Mycosis Fungoides in Critically Ill Cancer Patients. Oncologic Critical Care 2020. [DOI: 10.1007/978-3-319-74588-6_196] [Reference Citation Analysis]
26 Voorhees TJ, Bowers EV, Kelsey CR, Park Y, Beaven AW. Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome. Novel Therapeutics for Rare Lymphomas 2020. [DOI: 10.1007/978-3-030-25610-4_14] [Reference Citation Analysis]
27 Querfeld C, Rosen ST, Duvic M. Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00104-3] [Reference Citation Analysis]
28 Mahmut Y. Achievement of cure following allogeneic HSCT with Flu-Bu regimen in a patient with severe mycosis fungoides and Sezary Syndrome. Arch Case Rep 2019;3:054-055. [DOI: 10.29328/journal.acr.1001025] [Reference Citation Analysis]
29 Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
30 Novelli S, Monter A, Pilar García-Muret M, Martino R, Briones J, Sierra J. Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. Int J Hematol 2019;110:406-10. [PMID: 31317515 DOI: 10.1007/s12185-019-02707-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Narra RK, Shah NN. Allogenic Transplant for Non-Hodgkin Lymphoma. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00015-8] [Reference Citation Analysis]
32 Ramnaraign BH, Dang NH. Mycosis Fungoides in Critically Ill Cancer Patients. Oncologic Critical Care 2019. [DOI: 10.1007/978-3-319-74698-2_196-1] [Reference Citation Analysis]
33 Hosoi H, Hatanaka K, Murata S, Mushino T, Kuriyama K, Nishikawa A, Hanaoka N, Tamura S, Nakakuma H, Sonoki T. Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome. Hematol Rep 2018;10:7497. [PMID: 30283619 DOI: 10.4081/hr.2018.7497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Scarisbrick J. Staging of Mycosis Fungoides and Sézary Syndrome: Time for an Update? EMJ Hematol 2018. [DOI: 10.33590/emjhematol/10313097] [Reference Citation Analysis]
35 Dulmage BO, Kong BY, Holzem K, Guitart J. What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments. Curr Derm Rep 2018;7:91-8. [DOI: 10.1007/s13671-018-0214-0] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
38 Stranzenbach R, Theurich S, Schlaak M. [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma]. Hautarzt 2017;68:716-20. [PMID: 28785925 DOI: 10.1007/s00105-017-4023-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
39 Şanlı H, Akay BN, Saral S, Okçu Heper A, Topçuoğlu P. Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation. Turk J Haematol 2017;34:194-5. [PMID: 28008858 DOI: 10.4274/tjh.2016.0395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Vural S, Akay BN, Botsalı A, Atilla E, Parlak N, Okçu Heper A, Şanlı H. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. Turk J Haematol 2018;35:35-41. [PMID: 28533196 DOI: 10.4274/tjh.2016.0502] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
41 Hoppe RT, Kim YH, Advani RH. Mycosis Fungoides and Sézary Syndrome. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm121] [Reference Citation Analysis]
42 Smith GL. Radiation Therapy in the Management of Cutaneous T-Cell Lymphomas. Radiation Therapy in Hematologic Malignancies 2017. [DOI: 10.1007/978-3-319-42615-0_12] [Reference Citation Analysis]
43 Khan Mohammad Beigi P. Treatment. Clinician's Guide to Mycosis Fungoides 2017. [DOI: 10.1007/978-3-319-47907-1_6] [Reference Citation Analysis]
44 Gonzalez BR, Rosen ST, Querfeld C. Cutaneous T-cell lymphoma. Management of Lymphomas: A Case-Based Approach 2017. [DOI: 10.1007/978-3-319-26827-9_10] [Reference Citation Analysis]
45 Scholz C, Eucker J, Knauf W. Indolente (niedrig maligne) Non-Hodgkin-Lymphome. Facharztwissen Hämatologie Onkologie 2017. [DOI: 10.1016/b978-3-437-21214-7.00012-2] [Reference Citation Analysis]
46 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
47 Mehta-shah N, Dogan A. Treatment of T-cell lymphomas. Handbook of Lymphoma 2016. [DOI: 10.1007/978-3-319-08467-1_7] [Reference Citation Analysis]
48 Smith GL, Wilson LD, Dabaja BS. Mycosis Fungoides. Clinical Radiation Oncology 2016. [DOI: 10.1016/b978-0-323-24098-7.00079-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Zain J, Thomas SH. Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (T Cell). Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch58] [Reference Citation Analysis]
50 Pullarkat V, Forman SJ. Hematopoietic Cell Transplantation for Rare Hematologic Malignancies. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
52 Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2016;51:358-64. [PMID: 26595076 DOI: 10.1038/bmt.2015.280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
53 Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 2015;26:2490-5. [PMID: 26416896 DOI: 10.1093/annonc/mdv473] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
54 Perrone G, De Philippis C, Farina L, Corradini P. Peripheral T-cell lymphomas. Clinical Guide to Transplantation in Lymphoma 2015. [DOI: 10.1002/9781118863282.ch19] [Reference Citation Analysis]
55 Jacobsen ED. Stem cell transplantation for mycosis fungoides/Sézary syndrome. Clinical Guide to Transplantation in Lymphoma 2015. [DOI: 10.1002/9781118863282.ch23] [Reference Citation Analysis]
56 Hu SCS. Mycosis fungoides and Sézary syndrome: Role of chemokines and chemokine receptors. World J Dermatol 2015; 4(2): 69-79 [DOI: 10.5314/wjd.v4.i2.69] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Chmielowska E, Studziński M, Giebel S, Krause A, Olejniczak M, Grzanka A. Follow-up of patients with mycosis fungoides after interferon α2b treatment failure. Postepy Dermatol Alergol 2015;32:67-72. [PMID: 26015774 DOI: 10.5114/pdia.2014.40941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
58 Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50:1037-56. [PMID: 25798672 DOI: 10.1038/bmt.2015.6] [Cited by in Crossref: 218] [Cited by in F6Publishing: 237] [Article Influence: 27.3] [Reference Citation Analysis]
59 Panchal MR, Scarisbrick JJ. The utility of bexarotene in mycosis fungoides and Sézary syndrome. Onco Targets Ther 2015;8:367-73. [PMID: 25678803 DOI: 10.2147/OTT.S61308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
60 Pawar R, Kasi Loknath Kumar A, Woodroof J, Cui W, McGuirk J, Abhyankar S, Ganguly S, Singh A, Lin T, Aljitawi O. Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism. Case Rep Hematol 2014;2014:743856. [PMID: 25580315 DOI: 10.1155/2014/743856] [Reference Citation Analysis]
61 E28 Literaturhinweise und Internetadressen. Facharzt Hämatologie Onkologie 2015. [DOI: 10.1016/b978-3-437-21213-0.16001-2] [Reference Citation Analysis]
62 Goyal A, Carter JB, Sohani AR, Barnes JA, Hoang MP, Duncan LM. Sézary Syndrome. Atlas of Cutaneous Lymphomas 2015. [DOI: 10.1007/978-3-319-17217-0_6] [Reference Citation Analysis]
63 Mamez AC, Souchet L, Roos-Weil D, Uzunov M, Brun AL, Algrin C, Leblond V, Nguyen S. Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation. Bone Marrow Transplant 2015;50:304-6. [PMID: 25365069 DOI: 10.1038/bmt.2014.243] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
64 Venkatarajan S, Duvic M. Sézary syndrome: an overview of current and future treatment options. Expert Opinion on Orphan Drugs 2014;2:889-901. [DOI: 10.1517/21678707.2014.928616] [Reference Citation Analysis]
65 Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:837-51. [PMID: 25042790 DOI: 10.1002/ajh.23756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
66 Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49:1360-1365. [PMID: 25068422 DOI: 10.1038/bmt.2014.161] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
67 Dugas-breit S, Schulze H, Hallermann C. Neue und altbewährte Therapieoptionen bei Mycosis fungoides und Sézary-Syndrom - eine aktuelle Bestandsaufnahme. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2014;12:561-570. [DOI: 10.1111/ddg.12376_suppl] [Reference Citation Analysis]
68 Dalle S, Perier-muzet M, Balme B, Thomas L. Mycosis Fungoides and Sézary Syndrome. Cancer Consult: Expertise for Clinical Practice 2014. [DOI: 10.1002/9781118589199.ch50] [Reference Citation Analysis]
69 Magrath IT, Bellan C, Leoncini L, Venkatesh H. Non‐Hodgkin Lymphomas. eLS 2014. [DOI: 10.1002/9780470015902.a0002171.pub3] [Reference Citation Analysis]
70 Child F, Whittaker S. Primary Cutaneous T-cell Lymphoma. Evidence-Based Dermatology 2014. [DOI: 10.1002/9781118357606.ch34] [Reference Citation Analysis]
71 Mycosis Fungoides. Skin Lymphoma 2014. [DOI: 10.1002/9781118492505.ch2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Sézary Syndrome. Skin Lymphoma 2014. [DOI: 10.1002/9781118492505.ch3] [Reference Citation Analysis]
73 Ortiz-romero PL, Papadavid E. Systemic Treatment of Primary Cutaneous Lymphomas. Skin Cancer 2014. [DOI: 10.1007/978-1-4614-7357-2_29] [Reference Citation Analysis]
74 Querfeld C, Rosen ST. Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00107-7] [Reference Citation Analysis]
75 Atalla A, Hallack Neto AE, Siqueira DB, Toledo GC. Allogeneic hematopoietic stem cell transplantation in mycosis fungoides. An Bras Dermatol 2013;88:216-9. [PMID: 24346924 DOI: 10.1590/abd1806-4841.20132365] [Reference Citation Analysis]
76 de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, d’Incan M, Dereure O, Dalle S, Dompmartin A. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99:527-534. [PMID: 24213148 DOI: 10.3324/haematol.2013.098145] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
77 Moritz RK, Ditschkowski M, Klemke CD, Terras S, Schlaak M, Knorr M, Theurich S, Hegenbart U, Kremens B, Beelen DW, Stücker M, Kreuter A; working group "cutaneous lymphomas" of the Arbeitsgemeinschaft für Dermatologische Forschung (ADF), Germany. Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma - a case series of the ADF working group "cutaneous lymphomas". J Dtsch Dermatol Ges 2014;12:39-46. [PMID: 24134607 DOI: 10.1111/ddg.12212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Illidge T, Chan C, Counsell N, Morris S, Scarisbrick J, Gilson D, Popova B, Patrick P, Smith P, Whittaker S, Cowan R. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 2013;109:2566-73. [PMID: 24136145 DOI: 10.1038/bjc.2013.616] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
79 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
80 Zhang L, Zhang YZ. Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status. Cancer Biol Med 2013;10:1-9. [PMID: 23691438 DOI: 10.7497/j.issn.2095-3941.2013.01.001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
81 Beylot-barry M, Dereure O. Recommandations pour le traitement des lymphomes T cutanés. Les lymphomes cutanés 2013. [DOI: 10.1007/978-2-8178-0354-8_25] [Reference Citation Analysis]
82 Izu-belloso R, García-ruiz J. Treatment of Cutaneous Lymphomas: an Update. Actas Dermo-Sifiliográficas (English Edition) 2012;103:694-707. [DOI: 10.1016/j.adengl.2012.09.016] [Reference Citation Analysis]
83 Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol 2012;13:102-21. [PMID: 22311555 DOI: 10.1007/s11864-011-0179-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
84 Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012;4:75-89. [PMID: 22457602 DOI: 10.2147/CMAR.S9660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
85 Bagot M. Développement de traitements ciblés pour les lymphomes T cutanés. Revue de la littérature. Bulletin de l'Académie Nationale de Médecine 2012;196:631-641. [DOI: 10.1016/s0001-4079(19)31799-6] [Reference Citation Analysis]
86 Poligone B, Heald P. Menus for managing patients with cutaneous T-cell lymphoma. Semin Cutan Med Surg 2012;31:25-32. [PMID: 22361286 DOI: 10.1016/j.sder.2011.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
87 Literaturhinweise und Internetadressen. Facharzt Hämatologie Onkologie 2012. [DOI: 10.1016/b978-3-437-21212-3.10048-7] [Reference Citation Analysis]
88 van Besien K. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol 2011;23:681-91. [PMID: 21946246 DOI: 10.1097/CCO.0b013e32834bb88e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
89 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [PMID: 21990092 DOI: 10.1002/ajh.22139] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
90 Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant 2012;47:940-5. [PMID: 22020023 DOI: 10.1038/bmt.2011.201] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
91 Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011;155:150-66. [PMID: 21883142 DOI: 10.1111/j.1365-2141.2011.08852.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
92 Battistella M. [Cutaneous lymphoma at the Dermatology Day conference, Paris 2010]. Ann Dermatol Venereol 2011;138:H1-11. [PMID: 21703464 DOI: 10.1016/S0151-9638(11)70070-9] [Reference Citation Analysis]
93 Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, Popplewell L, Gaal K, Senitzer D, Kogut N, O'Donnell M, Forman SJ. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 2011;52:1463-73. [PMID: 21699453 DOI: 10.3109/10428194.2011.574754] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
94 Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012;47:65-72. [PMID: 21358679 DOI: 10.1038/bmt.2011.16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]